Floatz logo

Ebv Mrna Vaccine

Epstein-Barr Virus Associated Lymphoma

Ruijin HospitalvaccineActive
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

7 Active assets in the Epstein-Barr Virus Associated Lymphoma cohort.

Asset / SponsorPhaseRating
Tabelecleucel
Pierre Fabre Medicament
Phase 3BB
Valganciclovir
Viracta Therapeutics, Inc.
Phase 2B
Arginine Butyrate
HemaQuest Pharmaceuticals Inc.
Phase 2CCC
METHOTREXATE
University of Miami
Phase 2CCC
Hydroxyurea
University of Miami
Phase 2CCC

View all 17 →

Same molecule, other indications

Ebv Mrna Vaccine is also rated in:

Epstein-Barr virus-related tumorDormant
CC
Indicative ·
43 / 100
View asset →
HIV-associated cancerDormant
C
Indicative ·
39 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →